Esperion Therapeutics Company Insiders
| ESPR Stock | USD 2.52 0.05 2.02% |
Esperion Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Esperion Therapeutics suggests that virtually all insiders are panicking. Esperion Therapeutics employs about 240 people. The company is managed by 11 executives with a total tenure of roughly 560 years, averaging almost 50.0 years of service per executive, having 21.82 employees per reported executive.
Esperion Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-10-17 | Eric Warren | Disposed 107 @ 2.12 | View | ||
| 2024-07-17 | Eric Warren | Disposed 108 @ 2.59 | View |
Monitoring Esperion Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Esperion |
Esperion Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Esperion Therapeutics' future performance. Based on our forecasts, it is anticipated that Esperion will maintain a workforce of slightly above 240 employees by December 2024.Esperion Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of 0.0384 % which means that it generated a profit of $0.0384 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6079) %, meaning that it created substantial loss on money invested by shareholders. Esperion Therapeutics' management efficiency ratios could be used to measure how well Esperion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Equity is likely to grow to 0.48, while Return On Tangible Assets are likely to drop (1.07). As of 11/22/2024, Debt To Assets is likely to grow to 2.74, while Total Assets are likely to drop slightly above 181.9 M.As of 11/22/2024, Common Stock Shares Outstanding is likely to grow to about 108.3 M, while Net Loss is likely to drop (220.8 M).
Esperion Therapeutics Workforce Comparison
Esperion Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 38,026. Esperion Therapeutics maintains roughly 240 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.31. Esperion Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Esperion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Esperion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Esperion Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 4.6667 | 14 | 3 | 463,000 | 6,017 |
| 2023-09-01 | 0.6667 | 2 | 3 | 89,300 | 1,091 |
| 2023-06-01 | 4.0 | 20 | 5 | 268,811 | 3,165 |
| 2023-03-01 | 1.25 | 10 | 8 | 973,650 | 33,286 |
| 2022-12-01 | 0.6667 | 2 | 3 | 110,000 | 1,049 |
| 2022-09-01 | 0.4 | 2 | 5 | 9,606 | 8,180 |
| 2022-06-01 | 7.3333 | 22 | 3 | 667,711 | 5,004 |
| 2022-03-01 | 1.5 | 6 | 4 | 365,250 | 571.00 |
| 2020-12-01 | 2.0 | 2 | 1 | 210,700 | 10,700 |
| 2020-03-01 | 0.9 | 9 | 10 | 228,800 | 365,750 |
| 2019-12-01 | 1.0 | 2 | 2 | 80,000 | 2,315 |
| 2019-03-01 | 1.75 | 7 | 4 | 164,146 | 58,119 |
| 2018-12-01 | 0.2381 | 5 | 21 | 240,000 | 463,000 |
| 2018-09-01 | 0.4 | 2 | 5 | 100,000 | 25,000 |
| 2018-06-01 | 5.0 | 20 | 4 | 483,673 | 34,471 |
| 2018-03-01 | 1.3571 | 19 | 14 | 498,187 | 1,078,069 |
| 2017-12-01 | 0.25 | 4 | 16 | 27,272 | 586,523 |
| 2017-03-01 | 1.0 | 7 | 7 | 567,900 | 1,150,000 |
| 2015-06-01 | 0.875 | 7 | 8 | 56,000 | 634,929 |
| 2015-03-01 | 0.5 | 6 | 12 | 226,800 | 1,692,222 |
| 2014-12-01 | 0.1429 | 4 | 28 | 1,505,000 | 1,000,000 |
| 2014-09-01 | 2.0 | 2 | 1 | 270,000 | 25,000 |
| 2014-03-01 | 1.0 | 1 | 1 | 20,000 | 20,000 |
| 2013-09-01 | 2.5 | 75 | 30 | 28,502,136 | 12,479,735 |
| 2004-03-01 | 0.1538 | 2 | 13 | 26,157 | 392,542 |
| 2003-12-01 | 1.0 | 1 | 1 | 3,200 | 3,200 |
| 2003-09-01 | 2.0 | 2 | 1 | 30,000 | 20,000 |
Esperion Therapeutics Notable Stakeholders
An Esperion Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Esperion Therapeutics often face trade-offs trying to please all of them. Esperion Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Esperion Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sheldon Koenig | CEO President | Profile | |
| Benjamin JD | General Secretary | Profile | |
| Benjamin MBA | Chief Officer | Profile | |
| Glenn Brame | Chief Officer | Profile | |
| Tiffany MBA | Associate Communications | Profile | |
| Ben MBA | Chief Officer | Profile | |
| Betty Swartz | Chief Officer | Profile | |
| Eric RPh | Chief Officer | Profile | |
| Benjamin Looker | General Counsel | Profile | |
| MD FACC | Chief Officer | Profile | |
| Kenneth Fiorelli | Chief Officer | Profile |
About Esperion Therapeutics Management Performance
The success or failure of an entity such as Esperion Therapeutics often depends on how effective the management is. Esperion Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Esperion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Esperion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (3.14) | (2.98) | |
| Return On Assets | (1.02) | (1.07) | |
| Return On Equity | 0.46 | 0.48 |
Esperion Therapeutics Workforce Analysis
Traditionally, organizations such as Esperion Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Esperion Therapeutics within its industry.Esperion Therapeutics Manpower Efficiency
Return on Esperion Therapeutics Manpower
| Revenue Per Employee | 484.7K | |
| Revenue Per Executive | 10.6M | |
| Net Loss Per Employee | 871.9K | |
| Net Loss Per Executive | 19M | |
| Working Capital Per Employee | 186.8K | |
| Working Capital Per Executive | 4.1M |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.